This week's roundup of Houston innovators includes Joanna Nathan of Prana Thoracic, James Rees of BWT, and Aimee Gardner of SurgWise. Photos courtesy

Editor's note: In this week's roundup of Houston innovators to know — a special Labor Day edition, I'm introducing you to three local innovators across industries — from human resources to medical devices — recently making headlines in Houston innovation.

Joanna Nathan, CEO and founder of Prana Thoracic

Joanna Nathan joins the Houston Innovators Podcast and explains why she's taken on leading a medical device startup. Photo courtesy of Joanna Nathan

If there was a Houston innovation ecosystem playing card, Joanna Nathan would definitely have BINGO by now. From starting a startup while a student at Rice University and being an early hire of medical device company Saranas to leading investment at Johnson & Johnson's Center for Device Innovation, Nathan is headed back to the founder seat with Prana Thoracic, a new company planning to equip physicians with a better tool for lung cancer intervention.

"Unlike breast, prostate, and other types of cancers, we historically have not actively screened for lung cancer," Nathan says on this week's Houston Innovation Podcast. "Screening has only just begun in this world, and because of that, physicians still need the right tools to take early screening information and turn it into early intervention."

Last month, Nathan, who serves as CEO of the company, and Prana announced that Nucore Medical Inc., its wholly owned subsidiary, has been awarded a $3 million grant from CPRIT. Click here to read more and stream the podcast episode.

James Rees, chief impact officer at Botanic Water Technologies

James Rees is the Houston-based chief impact officer at BWT. Photo via LinkedIn

This probably isn't breaking news, but the world is on the midst of a water crisis. More than 2 million Americans don’t have access to clean drinking water, according to one study by the U.S. Water Alliance group.

To help close that water gap, international firm, Botanical Water Technologies, has plans to expand its presence in the United States with the Houston region being a strategic area to roll out the implementation of a patented water filtration technology. In addition, the group is launching a blockchain enabled trading platform with Fujitsu to help support the business.

“Water is finite,” says Houston-based James Rees, chief impact officer at BWT. “Due to global growth and climate conditions, we are going to have between 20 to 30 percent less water available to us by 2025. Communities are facing issues with water infrastructure. Some communities don't have water. This is where BWT plans to come in to help.” Click here to read more.Click here to read more.

Aimee Gardner, CEO and co-founder of SurgWise

Aimee Gardner is the CEO and president of Houston-based SurgeWise. Photo via surgwise.com

Over the course of the summer, Aimee Gardner has been writing strategic columns for startups with hiring tips. Her articles have focused on scaling quickly, why not to just trust your gut when hiring, and attracting and retaining a diverse workforce.

Gardner's advice is especially keen since she herself is a startup founder — but also has a Master's degree in organizational psychology. For years, she's been advising both her clients at her company SurgWise Consulting, but also students at Baylor College of Medicine.

"If your startup has gotten to the point of being able to grow the team, it is clear that ample vision, strategy, and innovation has been dedicated to the mission up until this point. Hiring in the next round of team members is not a process that should undergo any less dedication," she writes in one of her articles. "Ensuring that those around you share your vision, goals, and have a complementary set of skills and attributes will be critical to ensure success in your company’s growth and achievements." Click here to read her guest columns,

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

European spacecraft developer expands to Houston with U.S. business, new lab

houston hq

European aerospace manufacturer The Exploration Company has established its first U.S. entity and named Space City as its headquarters.

The company announced earlier this month that it has launched TEC Federal to support U.S. government customers and agencies, and to scale The Exploration Company's engineering operations in the country.

Mark Kirasich serves as president of TEC Federal. Kirasich most recently served as the senior director of human spaceflight at Blue Origin after a nearly 40-year career at NASA.

The Exploration Company is developing the reusable Nyx space vehicle. Nyx is designed to take off from any heavy launcher in the world. It will then dock at space stations, retrieve up to 3,000 kilograms of cargo, splash down and return the cargo to Earth. The company aims to make Nyx fully reusable for up to 10 missions, making it a more affordable and sustainable option for aerospace missions.

The Exploration Company completed a successful drop test of the spacecraft in May in the Mojave Desert. The company says Nyx is slated to perform its first flight demonstration in 2028.

In addition to launching the Houston business, The Exploration Company also opened its new Rapid Innovation Lab near Houston's NASA Johnson Space Center on Space Park Drive.

The Exploration Company opened its Rapid Innovation Lab earlier this month. Photo via LinkedIn

The Rapid Innovation Lab features a full-scale mockup of the future Nyx crew capsule as well as ongoing development and testing of the Nyx cargo capsule, according to the company.

The Exploration Company says the new lab will allow its engineers, designers, and operators to prototype and test crew interfaces. It will also support partnerships with NASA personnel and astronauts.

“Houston gives us direct access to the people and expertise that have built and operated human spaceflight systems for decades. We’re excited to invest and expand around that— engineers, operators, and astronauts working together and moving quickly towards building a crew capsule.” Hélène Huby, founder and CEO of The Exploration Company, said in a blog post.

According to The Houston Chronicle, The Exploration Company has about 30 employees in the Houston area.

The company was founded in 2021 by Huby, a French rocket scientist, and has raised more than $350 million in venture capital. It operates out of Germany, France, Luxembourg, Spain and Italy, with offices in the U.S. and the United Arab Emirates. It is also developing a reusable, high-thrust rocket engine known as Storm.

UH lands $4M NIH grant to study early signs of autoimmune disease

NIH funding

The University of Houston recently received a $4 million National Institutes of Health grant to support a 10-year longitudinal study to identify the earliest biological markers of autoimmune disease.

Led by Chandra Mohan, the Hugh Roy and Lillie Cranz Cullen Endowed Professor of Biomedical Engineering, the study aims to examine what causes Systemic Autoimmune Rheumatic Diseases (SARDs) and to identify targets for future treatments. The study will be carried out in collaboration with Dr. Karen Costenbader at Harvard Medical School, Boston.

SARDs include conditions like rheumatoid arthritis, systemic lupus erythematosus, Sjögren’s syndrome and systemic sclerosis—all are considered chronic diseases currently without a cure. Autoimmune diseases affect over 30 million people globally, according to UH.

SARDs occur when the body’s immune system attacks healthy, non-threatening tissues and organs. According to UH, in these diseases, the body often attacks nuclear antigens, creating anti-nuclear autoantibodies, which can be early detection signs for SARDs in more than 50 percent of patients, Mohan says.

Researchers will study blood samples and environmental exposure over the 10 years to better understand anti-nuclear autoantibodies.

“Collectively, these studies will help identify the genetic, environmental and cellular factors that are operative at the two steps of SARD development, namely the emergence of anti-nuclear autoantibodies and disease onset,” Mohan said in a news release. “ More importantly, these studies will highlight functional molecular pathways and mechanisms that may be operative at each step."

Mohan predicts that looking at SARDs’ shared characteristics, rather than each disease individually, could help identify more treatment methods.

“Individual SARDs have been examined in silos without an attempt to discern shared underlying features at the molecular level,” he added in the release. “Current understanding of the initial (and likely shared) origins of SARDs is only rudimentary but urgently needed to develop means for prevention and treatment.”

Earlier this year, UH also received an $11 million NIH grant to conduct a first-of-its-kind study of early language development in children ages 18 to 24 months. Read more here.